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Abstract
Background: There have been few reports of pharmacokinetic models that have been linked to models of the
cardiovascular system. Such models could predict the cardiovascular effects of a drug under a variety of
circumstances. Limiting factors may be the lack of a suitably simple cardiovascular model, the difficulty in managing
extensive cardiovascular data sets, and the lack of physiologically based pharmacokinetic models that can account
for blood flow changes that may be caused by a drug. An approach for addressing these limitations is proposed,
and illustrated using data on the cardiovascular effects of magnesium given intravenously to sheep.
The cardiovascular model was based on compartments for venous and arterial blood. Blood flowed from arterial
to venous compartments via a passive flow through a systemic vascular resistance. Blood flowed from venous to
arterial via a pump (the heart-lung system), the pumping rate was governed by the venous pressure (Frank-Starling
mechanism). Heart rate was controlled via the difference between arterial blood pressure and a set point
(Baroreceptor control). Constraints were made to pressure-volume relationships, pressure-stroke volume
relationships, and physical limits were imposed to produce plausible cardiac function curves and baseline
cardiovascular variables. "Cardiovascular radar plots" were developed for concisely displaying the cardiovascular
status. A recirculatory kinetic model of magnesium was developed that could account for the large changes in
cardiac output caused by this drug. Arterial concentrations predicted by the kinetic model were linked to the
systemic vascular resistance and venous compliance terms of the cardiovascular model. The kinetic-dynamic
model based on a training data set (30 mmol over 2 min) was used to predict the results for a separate validation
data set (30 mmol over 5 min).
Results: The kinetic-dynamic model was able to describe the training data set. A recirculatory kinetic model was
a good description of the acute kinetics of magnesium in sheep. The volume of distribution of magnesium in the
lungs was 0.89 L, and in the body was 4.02 L. A permeability term (0.59 L min-1) described the distribution of
magnesium into a deeper (probably intracellular) compartment. The final kinetic-dynamic model was able to
predict the validation data set. The mean prediction error for the arterial magnesium concentrations, cardiac
output and mean arterial blood pressure for the validation data set were 0.02, 3.0 and 6.1%, respectively.
Conclusion: The combination of a recirculatory model and a simple two-compartment cardiovascular model
was able to describe and predict the kinetics and cardiovascular effects of magnesium in sheep.
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Background
The effective use of some drugs can be limited by their
adverse effects on the cardiovascular system, particularly
when they are used intravenously in relatively high doses.
There have been many studies documenting the cardio-
vascular effects of drugs. Similarly, many mathematical
models of the cardiovascular system, of varying complex-
ity, have been presented in the literature [1,2]. In pioneer-
ing work, models of the cardiovascular system have been
linked to pharmacokinetic models of volatile anaesthetic
disposition [3-5]. These kinetic-dynamic models have
since been developed into mannequin based anaesthesia
simulators, which now have a pivotal role in the training
of anaesthetists. This approach has been facilitated by the
fact that models of volatile anaesthetic disposition have
traditionally been physiologically based (e.g. using repre-
sentations of tissue:blood partition coefficients and blood
flows for individual organs or groups of organs). It is
therefore possible to equate blood flow in the cardiovas-
cular model to blood flow in the pharmacokinetic model.
Nevertheless, a limiting factor in the implementation of
this approach is the availability of experimental data on
concentration-effect relationships [5].
In contrast, for traditional ("non-volatile") drugs, there
have been very few instances in which kinetic models of a
drug have been linked to cardiovascular pharmacody-
namic models. The work of Francheteau et al. is an impor-
tant exception [6], but even this early work was restricted
to analysis of only one aspect of the cardiovascular system
(i.e. accounting for heart rate mediated control of blood
pressure but not Frank-Starling control of cardiac output).
However, it is clear this approach has the potential to pro-
vide a more rational basis for designing dose regimens of
cardio-active drugs, and could provide insight into strate-
gies for controlling their cardio-vascular effects. It maybe
possible to predict a priori the cardiovascular conse-
quences of, for example, a change in dose regimen of a
drug.
There are a number of difficulties in implementing this
approach for traditional drugs. One problem is that most
drugs do not cause changes in one single cardiovascular
variable (such as blood pressure) that can be described in
the usual manner using a simple semi-empirical dynamic
model (e.g. an Emax model). Rather, a number of cardio-
vascular variables may be altered simultaneously in a
manner that is complex and interrelated. Thus, any
dynamic model used must account for these intrinsic rela-
tionships between cardiovascular variables. Another
problem is that changes in the cardiovascular system (in
particular blood flow distribution) invariably alter the
kinetics of the drug under study. Therefore, the kinetic
model of the drug must be able to account for the effects
of blood flow changes on the disposition of the drug. This
requires the kinetic model to have a physiological basis,
and importantly excludes the widely used mamillary com-
partmental pharmacokinetic model.
The general aims of this study were threefold. First, to
develop a simple dynamic model of the cardiovascular
system that was of sufficient complexity to account for the
major mechanisms by which drugs can alter cardiovascu-
lar variables. Second, to examine whether recirculatory
kinetic models [7] have sufficient physiological basis to
account for drug related blood flow changes. Third, to
examine approaches for identifying the important con-
centrations (and their sites in the body) that can be used
to link the kinetic and dynamic models.
The specific aim was to use previously published data col-
lected using a chronically instrumented sheep preparation
[8,9] to develop a kinetic-dynamic model for the cardio-
vascular effects of magnesium. Magnesium is given intra-
venously to treat a number of diseases, including pre-
eclampsia. It relaxes smooth muscles in blood vessels
thereby lowering systemic vascular resistance, with a con-
sequent decrease of mean arterial blood pressure and
increase in cardiac output. It provides a useful drug for ini-
tial analysis as its kinetics and dynamics are relatively sim-
ple and well understood.
The overall hypothesis of this work is that it is possible to
construct a faithful model of the cardiovascular effects of
drugs such as magnesium. While doing so requires more
assumptions and estimates of parameter values than nor-
mally associated with semi-empirical pharmacokinetic-
pharmacodynamic modelling, a physiological approach
greatly increases the utility of the resulting models. It is
proposed that the general methods presented here could
be applied to the development of similar models for other
drugs with acute cardiovascular effects.
Methods
General rationale
With respect to devising a pharmacodynamic model of
the cardiovascular system, the important steps are:
1. Identifying which cardiovascular variables (e.g. heart
rate, blood pressure) are important. This depends on the
drug and the intended use of the model, but it is proposed
that there is a minimum set of variables that is needed for
a basic description of cardiovascular status.
2. Devising a way of conveniently presenting the output of
the dynamic model for a range of cardiovascular variables
for comparison with data.
3. Identifying a cardiovascular model of the appropriate
complexity. Ideally the model must be of the minimumBMC Pharmacology 2005, 5:5 http://www.biomedcentral.com/1471-2210/5/5
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complexity that includes the cardiovascular variables
identified above, and the major sites of action of the
drugs.
4. Identifying which parameters of the cardiovascular
model can be estimated by curve-fitting, and which
require prior estimates or measurements of physiological
values. Most cardiovascular models are stiff numerical sys-
tems with many parameters, and only a small number can
be estimated by curve-fitting the data in the traditional
way.
With respect to the pharmacokinetic model, there remains
one crucial step:
5. Constructing a kinetic model with a physiological basis
that is sufficiently realistic to describe and predict the con-
centration of the drug in the key target organs controlling
the cardiovascular system. On first principles, these could
be expected to include:
a. the myocardial concentrations when the drug has a
direct myocardial effect (e.g. causes myocardial
depression);
b. the CNS concentrations when the drug affects the car-
dio-respiratory control centre of the brain;
c. the arterial blood concentration when the drug affects
baro-receptors or smooth muscle in the walls of the arte-
rial vascular system;
d. the venous blood concentration when the drug affects
smooth muscle in the wall of the capacitance vessels of the
venous vascular system.
It is known that these concentrations can follow different
time-courses, particularly after bolus administration or a
change of infusion rate [10,11]. However, it may not be
necessary to know the time-course of these concentrations
for every drug, depending on its mechanism of action.
Data sets and software
The data used to construct the model were collected in the
same laboratory using a conscious chronically instru-
mented sheep preparation and have been published pre-
viously [8,9]. This facilitated the model building process,
as the effect of differences in species and measurement
methods could be discounted.
Data set 1 [9] (for model development) was a detailed set
of cardiovascular measurements made after the adminis-
tration of 30 mmol of magnesium over 2 min to 5 sheep.
Measurements included arterial and coronary sinus (efflu-
ent from the heart) magnesium concentration, cardiac
output, mean arterial blood pressure, heart rate, an index
of myocardial contractility (Maximum positive rate of
change of left ventricular Pressure, dp/dt) and an index of
filling pressure (Left ventricular end diastolic pressure)
and myocardial blood flow. These were made until 25
min after the start of administration.
Data set 2 [8] (for model validation) was a less compre-
hensive set of cardiovascular measurements made after
the administration of 30 mmol of magnesium over 5 min
to 5 sheep (not the same sheep as Data set 1). Measure-
ments included arterial magnesium concentration, car-
diac output, and mean arterial blood pressure, and were
made until 25 min after the start of administration. The
blood pressure data for one animal in this data set was
excluded, as it was idiosyncratically low.
The time-course of the data averaged across sheep were
used for all modelling – the resultant model therefore rep-
resents the response of the average sheep. Inter- and intra-
animal variability were not considered, although it is
noted that the final model may provide insight into
sources of kinetic and dynamic variability for later study.
The software used was the Scientist for Windows program
(Version 2.01, Micromath, Salt Lake City, Utah, USA),
predominantly for curve-fitting. The R language, Version
1.9.0, [12] was used for graphical data analysis, data han-
dling and simulations. Coding the same model in the two
different programs provided a useful check for errors.
For the least squares curve-fitting, the best fit was deter-
mined as that with the highest Model Selection Criteria
(MSC) and without non-identifiable parameters. The
MSC is essentially an inverse Akaike Information Crite-
rion scaled to compensate for data sets of different magni-
tudes (Scientist for Windows manual, Micromath, Salt
Lake City, Utah, USA), and is calculated as follows where
wi is a weighting term, p is the number of parameters and
n is the number of data points:
All data points were weighted equally. A parameter was
arbitrarily defined as non-identifiable if the standard devi-
ation of the parameter returned by the fitting program was
greater than the parameter estimate (i.e. the coefficient of
variation was greater than 100%). A model with non-
identifiable parameters means that the data do not con-
tain sufficient information to estimate the parameter with
precision.
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The symbols used throughout have been based on stand-
ards for the pharmacokinetic literature. Unfortunately,
the use of C for both concentration (in pharmacokinetics)
and compliance (in cardiovascular physiology) creates of
conflict for this paper. To avoid confusion, CPL will be
used for compliance here.
Pharmacodynamic model of the cardiovascular system
Identification of important cardiovascular variables
The choice of the cardiovascular variables used in the
model is clearly dependent on the drug under study and
the intended purpose of the model. However, we propose
that a minimum of 7 fundamental cardiovascular varia-
bles is sufficient for most pharmacological purposes.
These variables are shown with their default unit of meas-
urement in the model: Central venous pressure (CVP,
mmHg), Myocardial contractility (CNT, L mmHg-1),
Stroke volume (SV, L), Heart rate (HR, min-1), Cardiac
output (CO, L min-1), Systemic vascular resistance (SVR,
Resistance units, RU) and mean arterial blood pressure
(MAP, mmHg).
This choice of variables requires several assumptions:
Assumption 1
All variables are time averaged in that beat to beat varia-
tion is ignored (e.g. mean arterial blood pressure is used
rather than systolic and diastolic blood pressures).
Assumption 2
That the function of the left and right side of the heart is
the same, and there are no abnormalities in the pulmo-
nary vasculature so that the heart-lung system can be
treated as one pump.
Assumption 3
Long time-scale events such as fluid shifts and renal mech-
anisms controlling blood pressure are ignored.
Furthermore, this choice of variables is dictated by several
fundamental relationships between the variables. Firstly,
that myocardial contractility is a proportionality constant
between CVP pressure and stroke volume (the volume of
blood pumped with each beat of the heart).
CVP * CNT ≈  SV  ...(2)
Mathematically, CNT must therefore have the units of vol-
ume / pressure. However, contractility is difficult to meas-
ure in vivo, and that there are a number of surrogate
measures including dp/dt. These can also be used with
appropriate scaling factors.
Assumption 4
That there are no factors affecting the relationship
between myocardial fibre length (the true determinant of
stroke volume) and central venous pressure (e.g. changes
in myocardial compliance). CVP is therefore used as an
easily measured index for myocardial fibre length – the
assumption is that the two are related using a scaling fac-
tor. Left ventricular end diastolic pressure is also as an
alternative index when data are presented as percent
change from baseline.
The second relationship is that between stroke volume
and heart rate to give the cardiac output (the volume of
blood pumped by the heart per unit time):
SV * HR = CO  ...(3)
The last relationship is that between cardiac output and
systemic vascular resistance to approximate the mean arte-
rial blood pressure.
CO/SVR ≈  MAP  ...(4)
This is because MAP usually greatly exceeds the CVP:
CO/SVR = MAP-CVP  ...(5)
SVR therefore has the units of pressure over flow. In this
paper, the resistance units (RU) are therefore mmHg L-1
min.
Presentation of relationships between cardiovascular 
variables
The effect of a drug on one or two variables can usually be
summarised on a plot of the variable (drug effect) against
time. However, it is more difficult to summarise the
dynamic effect of a drug on the cardiovascular system for
the following reasons: First, the large number of variables
required in the summary, where the seven described
above could be considered a minimum. Second, the fixed
inter-relationships (e.g. Eqns. 2–4) between these varia-
bles that should be revealed by the summary (e.g. if SV
increased by 25% and all else remains the same, then CO
should also increase by 25% (Eqn. 3)). Third, usually an
analysis requires comparing one cardiovascular state (e.g.
pre-drug) with another (e.g. post-drug), or examining the
time-course of drug effects.
It is proposed that a "cardiovascular radar plot" with a
modified logarithmic, normalised scale is an efficient
means of limiting these problems. An example radar plot
is shown and described in Fig. 1. Radar plots are particu-
larly useful for visually testing whether a model of the car-
diovascular system behaves appropriately for all 7 key
cardiovascular variables when challenged with aBMC Pharmacology 2005, 5:5 http://www.biomedcentral.com/1471-2210/5/5
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An example of a cardiovascular radar plot. Figure 1
An example of a cardiovascular radar plot. A cardiovascular radar plot of the effect of magnesium (n = 5 sheep) on the 
cardiovascular system under baseline conditions and for a number of time-points until 25 min after the intravenous administra-
tion of magnesium. A scale for each of the 7 key cardiovascular variables radiates from the centre of the plot. LVEDP (left ven-
tricular end diastolic pressure) is a surrogate for CVP; both should change proportionally. The data are transformed and the 
scale constructed so that 3 is the baseline (pre-drug) value. Thus, the blue line for the baseline data is a ring passing through 3 
for each variable. Baseline conditions therefore have a characteristic equilateral 7 sided shape. The full scale is structured as fol-
lows: 1 one quarter baseline 2 half baseline 3 baseline 4 twice baseline 5 4 times baseline This scale has the property that for an 
equivalent increase or decrease in a cardiovascular variable compared to baseline, the line will move an equal distance in or out 
from the baseline value. It can be seen that following magnesium there was a drop in SVR with a baroreflex increase in HR to 
compensate for the drop in blood pressure. LVEDP also dropped, but with minimal change in contractility. Drugs that affect 
the cardiovascular system via different mechanisms produce plots with characteristic shapes, which can be recognised with 
experience. Note: The order of the variables on the radar plot has been chosen to account for key relationships between the 
variables, with CVP (as given by LVEDP) as the most fundamental variable at the top: In an anti-clockwise direction the follow-
ing relationships or approximations hold: CVP * CNT ≈  SV SV * HR = CO CO/SVR ≈  MAP
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particular drug or physiological circumstance. It is partic-
ularly useful to see if the pattern of changes is internally
consistent. For example, in Fig. 1 it is clear that magne-
sium dropped SVR, but the drop in MAP was not great as
expected because there was a baroreceptor mediated
increase in heart rate.
Cardiovascular model – Structure and parameter 
estimation
There are many published models of the cardiovascular
system of various levels of complexity and intended for
various tasks [1]. However, in this paper, the cardiovascu-
lar model was constructed progressively from first princi-
ples, with adaptations and increases in complexity as
dictated by the requirements of the modelling process and
the data. This ensured the model was the minimum that
was needed for the task at hand.
In vivo, the cardiovascular system has two major control
systems; control of cardiac output via the Frank-Starling
mechanism, and control of blood pressure via barorecep-
tor control of heart rate. These were added progressively to
the model.
A simple Frank-Starling model
A simple model of the Frank-Starling mechanism was
developed (Fig. 2) assuming the blood is predominately
in two pools – the arterial and venous vasculature. The
two pools are connected by a pump (the heart) moving
blood from the venous to arterial side for which the rate
of pumping is proportional to the venous pressure. Blood
flows from the arterial to venous side through a passive
resistance (the SVR). The pressure in each pool is a func-
tion of the compliance in the pool. Compliance (CPL)
governs the relationship between volume and pressure:
Pressure = Volume/Compliance  ...(6)
A simple Frank-Starling model of the cardiovascular system Figure 2
A simple Frank-Starling model of the cardiovascular system. A simple two compartment model of the circulation, 
with control of the cardiac output via the Frank-Starling mechanism. When the heart is not pumping, the pressures on the 
venous (Pv) and arterial (Pa) sides of the circulation are equal (the mean circulatory pressure (MCP = Pv = Pa) is approximately 
7 mmHg). The unstressed volumes of the venous (Vv0) and arterial sides (Va0) are governed by the relative compliance of the 
venous and arterial pools (CPLv and CPLa, respectively). If the pumping action of the heart is initiated, a fraction of the blood 
(dV) moves from the venous to the arterial side thereby increasing arterial pressure and decreasing venous pressure. The pres-
sure gradient causes blood to flow from the arterial side to the venous side (at a rate given by the venous return, COR). This 
depends on the pressure gradient (Pa-Pv) and the systemic vascular resistance (SVR).
Venous Arterial
Vv = Vv0 - dV
pump
Pa = Va/CPLa
Va = dV + Va0
COr = (Pa-Pv)/SVR Pv = Vv/CPLv
passive flow
COl = kc*CNT*PvBMC Pharmacology 2005, 5:5 http://www.biomedcentral.com/1471-2210/5/5
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The solution to the simple Frank-Starling model can be
found algebraically, but for consistency is shown in Addi-
tional File 1 as differential equations.
Central to the Frank-Starling model is the concept of car-
diac function curves – usually given as the pressure in each
pool as cardiac function (contractility) is increased from
zero to a normal value. These curves are useful for finding
appropriate initial estimates for blood volume, arterial
and venous compliance, and systemic vascular resistance.
To achieve the physiologically plausible cardiac function
curve shown in Fig. 3, blood volume was set at 3.5 L [13].
Given that in a normal (50 kg) sheep the baseline cardiac
output is approximately 6 L/min and mean arterial blood
pressure is 100 mmHg (Table 1), baseline systemic vascu-
lar resistance is therefore 100/6 ≈  17 RU. The remaining
unknowns of this system (kc, CPLa, CPLv) were chosen to
duplicate the following behaviour (Fig. 3) which is con-
sistent with measurements in this species: When CNT is
zero (i.e. the heart is not pumping) then dV is zero and the
mean circulatory pressure (MCP) is approximately 7 mm
Hg. When CNT is such that the cardiac output is approxi-
mately 6 L min-1, then MAP and CVP are approximately
100 and 2 mmHg, respectively (Table 1). In practice, it
was found easier to express the arterial compliance (CPLa)
as the ratio of arterial compliance to venous compliance
(Cratio).
Frank-Starling and Baroreceptor model
The control of arterial blood pressure via baroreceptor
control of heart rate was added to the simple Frank-Star-
ling model, as shown in Fig. 4. The arterial pressure set
point (MAPset) was used to calculate the difference
between the actual and set pressure (MAPdelta). This pres-
sure difference was used to change heart rate with a gain
given by "HRgain". When HRgain is zero, the model
reduces to the simple Frank-Starling model. As HRgain is
increased, the more heart rate is adjusted to defend
changes in arterial pressure. A value of 3 was initially used
for HRgain. The resultant cardiac function curve for this
model is shown in Fig. 5, and the equations for the model
are shown in Additional File 2.
Constraining the model to increase physiological plausibility
The final version of the model introduced a number of
constraints to increase its physiological plausibility. These
were: 1) Assuming that under baseline conditions that
approximately 1/3 of the total blood pool is in the arterial
system. 2) That the intercepts of the pressure-volume
"curves" for the venous and arterial compartments were
linear such that both curves gave the mean circulatory
pressure (MCP) at the unstressed volumes (Vv0 and Va0,
see Fig. 6). 3) That the venous pressure could not be less
than zero, and that the arterial pressure could not be less
than the MCP. 4) That heart rate was constrained to be
between 0 and 220. 5) That the venous pressure – stroke
volume relationship was non-linear and reached a plateau
consistent with the finite pumping capacity of the heart
(Fig. 6). 6) For convenience, two additional parameters
were introduced (S1 and S2) representing the state of the
sympathetic nervous system. These gave the capacity to
adjust the proportionality term between blood pressure
and heart rate (HRgain) and between CVP and stroke vol-
ume (kc). This allowed these scaling constants to be sepa-
rated into a constant term that is solely used to convert
measurement units (HRgain or kc) and another term (S1
or S2) that represents changes in underlying physiology
for use when fitting data. Their normal values were 1 in
each case (giving no effect for baseline conditions) and
their function is summarised in the following equations:
HR = MAPset + MAPdelta*(HRgain*S1)  ...(7)
The resultant cardiac function curves for this model are
shown in Fig. 7, and the equations for the model are
shown in Additional File 3.
Baseline values for the cardiovascular model
For convenience, the target cardiovascular variables of the
final constrained model discussed above are summarised
in Table 1 with references to their origins. The parameter
set that produced cardiovascular variables similar to the
target values is summarised in Table 2. This was derived
semi-empirically by inspection of cardiovascular function
curves (Fig. 7) and pressure-volume relationships (Fig. 6)
with incremental adjustment of parameter values. Note
that some variables are also listed as parameters – this is
purely for convenience. The distinction between variables
(time-dependent) and parameters (time-independent) is
semantic and depends on the proposed use of the model.
The sensitivity of the baseline cardio-vascular model to
changes in parameter values was determined via Monte-
Carlo simulation [14]. Multi-variate normally distributed
noise was added to the parameter values for a series of
10,000 simulations of the resulting cardiovascular varia-
bles. Those parameter sets that produced a set of cardio-
vascular variables within 10% of the target set were
selected and analysed for with respect to parameter varia-
bility and correlation.
Fitting the cardiovascular model to the magnesium data
Changes in cardiovascular variables with the administra-
tion of magnesium were analysed as percentage change
from baseline. This removed the contribution of inter-ani-
mal variability in baseline cardiovascular variables (which
was nevertheless minor [8,9]) to variability in the
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Cardiac function curves for the Frank-Starling model Figure 3
Cardiac function curves for the Frank-Starling model. A summary of the behaviour of the simple Frank-Starling model. 
The relationship between cardiac function (contractility) and the arterial and venous pressures matches well that reported in 
many textbooks. The venous compliance CPLv was 0.45, and the ratio of CPLv/CPLa was 15.
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Table 1: Baseline (pre-drug) cardiovascular variables. A set of target values that was representative of the sheep studied in our 
laboratory was compiled from previous measurements and literature values as indicated. A set of parameter values for the final 
(Constrained-Frank-Starling-Baroreceptor) was derived (Table 2) that produced an internally consistent model that closely replicated 
these target values (also shown for comparison).
Variable Name Target 
Value
Target value origin Model 
derived 
Value
Units
Vblood Blood volume 3.5 literature [13] 3.5 L
CVP Central venous pressure 2.00 unpublished previous measurements and literature [20] 2.00 mmHg
CPLv Venous compliance 0.45 inferred from Vblood & CVP 0.46 L mmHg-1
MAP Mean arterial pressure 100 previous measurements [21] 100.9 mmHg
SVR Systemic vascular resistance 17.00 calculated from CO & MAP 17.0 RU
CO Cardiac output 6 previous measurements [21] 5.8 L min-1
HR Heart rate 100 previous measurements [21] 98.3 beats min-1
SV Stroke volume 0.06 calculated from CO & HR 0.059 L
CNT Contractility 3000 previous measurements [9, 21] 3000 mmHg sec-1
S1 Sympathetic tone – chronotropy 1 scaling factor only 1 dimensionless
S2 Sympathetic tone – Contractility 1 scaling factor only 1 dimensionless
A Frank-Starling-Baroreceptor model of the cardiovascular system Figure 4
A Frank-Starling-Baroreceptor model of the cardiovascular system. The Frank-Starling model of the circulation from 
Fig. 2 combined with baroreceptor control of arterial blood pressure (Pa) via changes in heart rate (HR). MAPset is the set point 
of the control system, and HRgain is the gain of the control system that operates on the difference between the actual and set 
arterial blood pressures (MAPdelta; Eqn. 7). The right side cardiac output term is expanded to include the role of myocardial 
contractility (CNT), stroke volume (SV) and heart rate (HR). "kc" is a conversion factor to adjust for the index used to meas-
ure myocardial contractility (Eqn. 8). Strictly, myocardial contractility is the proportionality factor between Pv and stroke vol-
ume (SV = COR/HR). However, it is often quantified using indirect indices, such as maximum positive change of ventricular 
pressure (dP/dtmax). The value of kc will depend of what index of contractility is used (see Eqn. 8).
Venous Arterial
Vv = Vv0 - dV
pump
Pa = Va/CPLa
Va = dV + Va0
COr = (Pa-Pv)/SVR Pv = Vv/CPLv
passive flow
COl = x.Pv
x = kc*CNT*SV*HR
HR = MAPset+MAPdelta*HRgain
MAPdelta= MAPset-PaBMC Pharmacology 2005, 5:5 http://www.biomedcentral.com/1471-2210/5/5
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Cardiac function curves for the Frank-Starling-Baroreceptor model Figure 5
Cardiac function curves for the Frank-Starling-Baroreceptor model. A summary of the behaviour of the Frank-Star-
ling-Baroreceptor model. The relationship between cardiac function (contractility) and the arterial and venous pressures 
matches well that reported in many textbooks. However, the vascular volumes show the majority of the blood in the arterial 
compartment, which is at odds with the fact that the majority of the blood under baseline conditions is in the venous vessels. 
Furthermore, no constraints have been placed on the model so that unrealistic values (e.g. large negative pressures) can be 
achieved in some circumstances.
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Effect of introducing constraints on the model Figure 6
Effect of introducing constraints on the model. Top: Venous pressure – volume curves. Venous volume starts at Vv0 
when the heart is not pumping, at which point the venous pressure is the mean circulatory pressure (MCP). With increased 
pumping, the venous volume and venous pressure is reduced. In the simple (Frank-Starling-Baroreceptor) model, the CVP – 
volume relationship was linear, with an intercept of zero. In the constrained model, a lower intercept was used which was nec-
essary to produce realistic venous volumes under baseline conditions. The multiple curves in the plot show the effect of chang-
ing venous compliance (CPLv). Middle: Arterial pressure – volume curves. Arterial volume starts at Va0 when the heart is not 
pumping, at which point the arterial pressure is the mean circulatory pressure (MCP). With increased pumping, the arterial vol-
ume and arterial pressure are increased. In the simple model, the MAP – volume relationship was linear, with an intercept of 
zero. In the constrained model, a lower intercept was the used, which was necessary to produce realistic arterial volumes 
under baseline conditions. The multiple curves in the plot show the effect of changing compliance (CPLa). Bottom: "Cardiac 
output curves" In this case cardiac output is given by stroke volume, which is plotted against central venous pressure (CVP). In 
the simple model, this relationship was linear. In the constrained model the relationship was given by a logistic equation which 
rose to a limit. The left-hand side of the curves are pseudo-linear, and the slope of the lines increase with increasing contractil-
ity. This behaviour mimics the "Cardiac output curves" found in many cardiovascular textbooks (e.g. Guyton [19]).
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Cardiac function curves for the Constained-Frank-Starling-Baroreceptor model Figure 7
Cardiac function curves for the Constained-Frank-Starling-Baroreceptor model. A summary of the behaviour of 
the final cardiovascular dynamic model.
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Best fit cardiovascular radar plots for each key time point Figure 8
Best fit cardiovascular radar plots for each key time point. Cardiovascular radar plots of the observed data (blue) and 
the best fit of the final cardiovascular model (red). Note that the shape of the radar plot changes with time, indicating the 
evolving effects of magnesium on the circulation. For each time-point, the fit was an adequate account of the data (Table 3).
Table 2: Baseline model parameters The parameters chosen as those producing representative baseline (pre-drug) cardiovascular 
variables (Table 1). The co-efficient of variation (CV (%)) of these parameter values as determined by the Monte-Carlo sensitivity 
analysis is also shown.
Parameter Name Value Units CV (%)
CPLv Venous compliance 0.45 L mmHg-1 12.7
CPLratio Ratio of venous over arterial compliance 20 dimensionless 17.7
Vblood Blood volume 3.5 L 17.9
SVR Systemic vascular resistance 17 RU 5.5
MAPset Mean arterial pressure set point 100 mmHg 4.2
HRgain Gain for heart rate control 1.8 bpma mmHg-1 23.6
CNT Contractility 3000 mmHg sec-1 4.9
abpm = beats per minute
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cardiovascular effects of magnesium. The analysis
involved fitting cardiovascular radar plots to the measured
magnesium data (Data set 1) for key time-points (1, 2, 4,
10 and 25 min) during and after magnesium
administration. The cardiovascular model was parameter-
ised in terms of primary cardiovascular variables that
could be directly influenced by magnesium. These were
SVR, CPLv, CPLratio, CNT, S1 and S2. Vblood could also be
considered a primary variable, but it was considered
unlikely that magnesium could change the blood volume.
The remaining cardiovascular variables were considered
secondary in that they would change in response to
changes in the primary variables as given by Eqns 2 to 4.
Initially, the only primary parameter fitted to the data for
each time point was SVR while the other parameters were
held constant. This was based on the prior knowledge that
this was the primary mechanism of action of magnesium.
If the MSC was low and the cardiovascular radar plot
showed a poor fit between model predictions and the
data, an additional parameter was fitted one at a time
from the remaining parameters listed above. A parameter
was removed from the fit if it produced an undefined esti-
mate. The parameter was kept in the fit if it improved the
MSC and the fidelity of observed vs. predicted plots on the
cardiovascular radar. By this process, the values of the pri-
mary cardiovascular parameter at each key time point
required to describe the observed data were determined.
Recirculatory pharmacokinetic model of magnesium 
disposition
Conventional mamillary pharmacokinetic models are
essentially empirical and do not include parameters
(other than clearance) that represent defined
physiological processes. This is problematic when drugs
affect the cardiovascular system, or it is necessary to pre-
dict the kinetics of the drug when the underlying physiol-
ogy has changed. This was the case for magnesium, which
affected cardiac output significantly (Figs. 1 &10). Full
physiological pharmacokinetic (PBPK) models are an
alternative, but often require extensive data sets for their
parameterisation. Recirculatory models have been used
[7,15] as an alternative that retain the key physiological
descriptions of important organs, but have lumped
descriptions of the less important organs. Often, they can
be parameterised by fitting blood concentrations alone.
The magnesium concentration data from Data set 1 were
used to develop a recirculatory model of magnesium
kinetics that could account for the observed cardiac
output changes. The processed used was similar to that
described by the authors for other drugs [15]. The final
form of the model is shown in Fig. 9.
Key points during the model development process were:
1) The representation of the lungs as a single compart-
ment. 2) The representation of the cardiac output change
as an empirical forcing function (see Fig. 10, this would
later be replaced by the predictions of the final cardiovas-
cular model). 3) The representation of the body as extra-
cellular and intracellular spaces connected by a
permeability term, in keeping with the known slow cellu-
lar uptake of magnesium. 4) The clearance of magnesium
is renal, but it can be reabsorbed or excreted in the
tubules, as dictated by homeostatic requirements [16].
Thus, renal clearance may be variable.
To confirm that the kinetics of magnesium were cardiac
output dependent, the final kinetic model was subjected
to a sensitivity analysis for this parameter. Cardiac output
was assigned values of 2, 4, 6, 8 or 10 L min-1 while the
other parameters were fixed at their best fit value. The
time-course of the arterial magnesium concentration was
recorded in each case.
Linking the pharmacokinetic and pharmacodynamic 
models
The relationship between the key cardiovascular parame-
ters (effects) and the concentrations of magnesium in arte-
rial and coronary sinus blood were examined using
hysteresis plots (effect vs. concentration). A concentra-
Final recirculatory pharmacokinetic model for magnesium Figure 9
Final recirculatory pharmacokinetic model for mag-
nesium. A pictorial representation of the model. Parameter 
names are given in Table 4.
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Best fits for the recirculatory pharmacokinetic model for magnesium Figure 10
Best fits for the recirculatory pharmacokinetic model for magnesium. Top: The observed changes in cardiac output 
for Data set 1 (symbols). Also shown is the line of best fit for the empirical forcing function used for development of the kinetic 
model. The large and consistent increase in cardiac output illustrates why it was necessary to use a kinetic model that could 
account for the significant flow changes caused by magnesium. Middle: The observed arterial concentrations of magnesium for 
Data set 1 (symbols). Also shown is the line of best fit for the final kinetic model (not linked to the cardiovascular model) based 
on the parameter values given in Table 4. Bottom: A sensitivity analysis of the final kinetic model with respect to cardiac output 
when used to simulate the dose regimen used for Data set 1. Cardiac output was given values of 2, 4, 6, 8 or 10 L min-1 while 
the other parameters were fixed at the values given in Table 4. This illustrates how the cardiac output changes caused by mag-
nesium can influence its own kinetics. This feedback process was inherent in the structure of the final kinetic-dynamic model.
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tion-effect relationship was considered plausible if pro-
duced a predictable relationship with minimal hysteresis
that was consistent with the known mechanisms of action
of the drug.
By these criteria, it was found that the arterial concentra-
tions were the better predictor of the fitted cardiovascular
parameters shown in Table 3. The concentration – effect
relationships are summarised in Fig. 11. The major effect
of magnesium was to drop systemic vascular resistance
(SVR). SVR was related to the arterial magnesium concen-
tration by a link model based on a linear relationship with
a threshold (Fig. 11A):
if Cart < 2.66 then
SVR = 17
else
SVR = -1.759*Cart + 21.68  ...(9)
Magnesium also raised venous compliance (CPLv). This
was related to the arterial concentration using a simple
threshold (Fig. 11B):
if Cart < 2 then
CPLv = 0.45
else
CPLv = 0.50  ...(10)
Magnesium had little effect on myocardial contractility
(Fig. 11C), and the linking function assumed that CNT
remained at baseline values. Magnesium appeared to
increase the sympathetic tone coefficient for contractility
(S2) by approximately 25% at between concentrations of
2 and 4 mmol L-1 (Fig. 11D). However, this rise in S2 only
occurred late in the study (Table 3). It indicates subtle
changes in the relationship between the filling pressure
index (LVEDP) and the contractility index (dp/dt). This
may reflect measurement error in these variables, non-sta-
tionarity in the experimental preparation or subtle
delayed changes in myocardial compliance caused by
magnesium. However, it was found that a link function
assuming S2 remained at baseline values (Fig. 11D) was
an adequate account of the data and did not compromise
the predictive power of the model in the validation stage.
The final kinetic-dynamic model therefore consisted of
the kinetic model shown in Fig. 9 linked to the
Constrained-Baroreceptor-Frank-Starling cardiovascular
dynamic model (Figs. 4 &7) via the link Equations 9 and
10. This is summarised in Fig. 12. The equations for the
model are shown in Additional file 4.
Validation of the final model
The final kinetic-dynamic model developed using Data set
1 was used to predict the arterial magnesium concentra-
tions, cardiac output and mean arterial blood pressure for
Data set 2. Data set 2 differed from Data set 1 in that the
dose of magnesium was given over 5 min instead of 2
min. Consequently, although the dose was the same, the
cardiovascular effects were less pronounced. For example,
the lowest blood mean arterial pressure for Data set 1 was
76% of baseline, while for Data set 2 this was 86% of
baseline. The only change made to the parameters of the
final model was to alter the duration of infusion of the
magnesium.
Results
Parameter sensitivity of cardiovascular model (baseline 
conditions)
The baseline cardiovascular variables and the parameters
that produced them are summarised in Tables 1 and 2,
respectively. Of the 10,000 random parameter sets exam-
ined in the Monte-Carlo sensitivity analysis, only 37 pro-
duced a set of cardiovascular variables that was within
10% of the target cardiovascular variables. The variability
of these successful parameter values was low (Table 2),
Table 3: The fitted primary cardiovascular parameters for Magnesium data set 1 Units are as for Table 2. The parameter estimates 
are given with the standard deviation returned by the curve-fitting program. S1 could not be reliably fitted to the data.
0 min 1 min 2 min 4 min 10 min 25 min
Fitted parameter (baseline) estimate (sd) estimate (sd) estimate (sd) estimate (sd) estimate (sd)
MSC n/a 3.88 2.96 4.75 1.67 4.74
CPLv 0.45 0.490 (0.0028) 0.495 (0.0075) 0.497 (0.0019) 0.505 (0.0049) 0.492 (0.0007)
SVR 17 11.99 (0.12) 9.84 (0.26) 11.84 (0.084) 14.64 (0.27) 16.74 (0.077)
CNT 3000 2988 (41) 3031 (104) 3388 (32) 3108 (80) 3180 (23)
S2 1 0.978 (0.023) 0.972 (0.055) 0.877 (0.014) 1.22 (0.06) 1.25 (0.017)BMC Pharmacology 2005, 5:5 http://www.biomedcentral.com/1471-2210/5/5
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and the spread of each parameter showed a unimodal,
approximately normal distribution. This suggests that
there was a unique set of parameter values for the model
that was consistent with normal baseline physiology. Vis-
ual inspection showed no obvious correlation between
parameter values, except for CPLv and CPLratio (correlation
coefficient = 0.83). This suggests that specifying the value
for one of these parameters significantly constrains the
value that can be taken for the other, as would be expected
on physiological grounds. It can be concluded that each
parameter had an important role to play in the model,
and that each could only take a limited range of values to
be consistent with the required baseline physiology. By
extension, the assumptions regarding the values of these
parameters are likely to be appropriate. Furthermore, the
changes in these parameters observed following magne-
sium administration therefore reflect the effects of this
drug rather than uncertainty in the parameter space of the
model.
Parameter estimates – cardiovascular data
The method of estimating cardiovascular model parame-
ters from cardiovascular data for individual time points
was effective. Thus, it was possible to find a parameter set
at each time point (Table 3) that produced a fitted cardio-
vascular radar plot that closely matched the observed plot
(Fig. 8). In general, the parameter estimates were precise.
The most obvious effect of magnesium was a drop in sys-
temic vascular resistance and a rapid and sustained
increase in venous compliance. The changes in the other
cardiovascular variables (e.g. HR and MAP) simply
reflected reflex changes in response to these primary drug
effects.
Parameter estimates – pharmacokinetic data
The recirculatory pharmacokinetic model was able to fit
the observed concentrations with adequate fidelity (Fig.
10, middle) and produce precise parameter estimates
(Table 4). As the clearance of magnesium was low, it
would be expected that the permeability term into the
deep compartment governed the rate of decline of the
magnesium concentration rather than its clearance from
the body.
A feature of recirculatory pharmacokinetic models is that
their initial kinetics are governed by first-pass passage of
drug through the lungs, and the dilution of the injected
drug with the cardiac output [7]. The cardiac output sen-
sitivity analysis for the model confirmed this behaviour
for magnesium (Fig. 10, bottom). This reinforces the need
for a common cardiac output term for the cardiovascular
and recirculatory kinetic model (Fig. 12). The resultant
final model therefore accounts for the fact that by altering
cardiac output, magnesium alters its own kinetics.
Link models for concentration-effect relationships Figure 11
Link models for concentration-effect relationships. A: 
The systemic vascular resistance (SVR) parameter (symbols, 
obtained by the fitting process that gave the radar plots 
shown in Fig. 8 and summarised in Table 3) plotted against 
the concurrent exogenous arterial magnesium concentra-
tions. The final link model (Eqn. 9; line) based on a linear rela-
tionship with a threshold is also shown. B: The venous 
compliance (CPLv) parameter (symbols, via Fig. 8) plotted 
against the concurrent exogenous arterial magnesium con-
centrations. The final link model (Eqn 10; line) based on a 
simple threshold that switches between two states of venous 
compliance is also shown. This is plausible if it is considered 
that magnesium, even at relatively low concentrations, causes 
maximal dilation of the venous capacitance vessels. C: The 
contractility (CNT) parameter (symbols, via Fig. 8) plotted 
against the concurrent exogenous arterial magnesium con-
centrations. The final link model (line) was based on the 
assumption that contractility was unaffected by magnesium 
(i.e parameter value was fixed). D: The sympathetic tone 
coefficient for contractility (S2) parameter (symbols, via Fig. 
8) plotted against the concurrent exogenous arterial magne-
sium concentrations. The final link model (line) was based on 
the assumption that S2 was unaffected by magnesium (i.e 
parameter value was fixed).
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Link functions
Relating the estimated cardiovascular parameters in Table
3 to the concurrent arterial concentrations produced the
concentration-effect curves shown in Fig. 11. Link func-
tions were established for SVR and CPLv, but not CNT or
S2. The overall role of the link functions is summarised in
Fig. 12.
Model validation – pharmacokinetic component
The recirculatory model of magnesium disposition was
able to accurately predict the time-course of the arterial
magnesium concentrations observed for the validation
Data set 2, despite the large change in cardiac output pro-
duced by magnesium (Fig. 13). The mean prediction error
was 0.02%
Overview of the kinetic-dynamic model linking process Figure 12
Overview of the kinetic-dynamic model linking process. A schematic representation of how the final model was 
derived from Data set 1. The pharmacokinetic (PK) component of the model was developed by fitting the observed arterial 
magnesium concentrations (Fig. 10, middle). As cardiac output was a parameter of the recirculatory model, the magnesium 
induced changes in cardiac output were represented as a forcing function during fitting (Fig. 10, top). In the final model, this 
forcing function was replaced by the cardiac output predicted by the cardiovascular (CV) model. For the CV model, target 
baseline cardiovascular variables were derived from previous measurements and the literature (Table 1). A unique parameter 
set for the CV model was found that reproduced these values (Table 2). To account for the changes in cardiovascular variables 
from baseline following magnesium, four parameters (SVR, CPLv, CNT and S2) were fitted to the observed magnesium CV data 
(expressed as change from baseline) at selected time-points (Fig. 8; Table 3). Of these, two parameters (SVR, CPLv) showed 
concentration dependent changes that could be related via link functions to the time-course of magnesium concentrations (Fig. 
11). The other parameters of the CV model were fixed at their baseline values. The final model was able to predict the concen-
trations and CV effects of magnesium for a different dose regimen (Data set 2, Fig. 13).
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Table 4: The fitted pharmacokinetic parameters for the 
Magnesium data set 1 The parameter estimates are given with 
the standard deviation returned by the curve-fitting program.
Fitted variable Value Units
MSC 3.13
Vlung 0.887 (0.221) L
CL 0.0021 (0.1286) L min-1
Vbody 4.023 (0.486) L
PS 0.589 (0.227) L min-1
Vdeep 8.63 (5.39) LBMC Pharmacology 2005, 5:5 http://www.biomedcentral.com/1471-2210/5/5
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Observed and predicted results for Data set 2 Figure 13
Observed and predicted results for Data set 2. The final kinetic-dynamic model developed using Data set 1 was used to 
predict the exogenous arterial magnesium concentrations (Cart,x), cardiac output (CO) and mean arterial pressure (MAP) for 
Data Set 2. The only change in the model between the two data sets was to increase the duration of the infusion from 2 to 5 
min. The observed data are shown as symbols, together with the upper and lower 95% confidence intervals of the data (dotted 
lines). The predictions of the model are shown by the solid lines.
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Model validation – pharmacodynamic component
The final pharmacodynamic model was able to accurately
predict the time-course of the cardiac output changes
observed for the validation Data set 2 (Fig. 13). The mean
prediction error was 3.0%.
The dynamic model captured the general trend of the
mean arterial blood pressure for the validation data (Fig.
13), but some systematic deviations were evident. The
model was accurate until the end of the infusion, but
thereafter slightly over-estimated the rate of recovery of
blood pressure. However, the model did predict that the
drop in blood pressure would be considerably less for a 5
min versus 2 min infusion, and the overall magnitude of
the changes in blood pressure for the 5 min infusion were
small (less than 10% change). The mean prediction error
was 6.1%.
Discussion
Concentration-effect relationships and recirculatory 
models
In this paper, all cardiovascular effects were related to the
arterial concentration of magnesium. As covered in the
introduction, there may be other sites in the body that
have a theoretical claim to being the most appropriate
link concentration for certain cardiovascular dynamic
effects. For example, the reductions in myocardial con-
tractility caused by thiopental have been shown to have a
better temporal relationship to the thiopental
concentrations in the myocardium itself rather than in
arterial blood [17]. This consistent with a direct thiopen-
tal effect on the myocardium.
In recirculatory models, it is possible to add a "target
organ" to represent organs such as the heart [18]. The fact
that this was not necessary for magnesium may be the
exception rather than the rule. As magnesium has small
volumes of distribution, there is little difference in the
time-course of the arterial and regional venous
concentrations. Furthermore, the predominant effects of
magnesium were directly on blood vessels (arterioles for
SVR and large veins for capacitance) in direct equilibrium
with blood rather than organs such as the heart or brain.
Thus, a "systemic" recirculatory model was sufficient for
magnesium. As other drugs are studied using this method,
data on target organ kinetics and their incorporation into
the kinetic model may be necessary.
Limitations
There are a number of limitations of this modelling
approach, many of which are inherent in the assumptions
made in the construction of the model. Other limitations
may become apparent if the model is used outside of the
range of the data used to develop the model. For example,
the CL term in the kinetic model was very low (Table 4).
This may reflect extensive tubular re-absorption, but may
also reflect the fact that the concentrations were followed
for only 25 min in the original paper (the time by which
most cardiovascular variables had returned to baseline).
Studies of a longer duration would help to define this
clearance term better.
The cardiovascular model also assumes an instantaneous
baroreceptor response. While it is relatively easy (in mod-
elling terms) to add a delay to this response, this was not
supported by the data. However, if the model is extended
to situations with very rapid blood pressure changes (e.g.
orthostatic hypotension) this deficiency may become
significant.
Constructing physiologically based models, even of the
simplicity presented here, requires crossing many deci-
sions points where a choice must be made from multiple
options – sometimes the choices are data driven, some-
times theory driven, sometimes the subjective experience
of the model maker must be called upon. While a "wrong"
model is evident because it does no match the data, there
is clearly no "right" model of the cardiovascular system. It
is anticipated that more limitations of the cardiovascular
dynamic model will become apparent when model is
rigorously compared to data for other drugs, and for other
cardiovascular scenarios. It is should be expected that the
model will continue to evolve as these data are collected
and analysed.
Conclusion
The combination of the recirculatory kinetic model and
the simple cardiovascular dynamic model was able to
describe and predict the concentrations and cardiovascu-
lar effects of magnesium in sheep. It is proposed that the
general methods used here could be applied to other
drugs with cardiovascular effects. The authors are cur-
rently applying the method to intravenous anaesthetics.
Abbreviations
Cardiovascular term Description
Frank-Starling model
Vblood Blood volume
CVP = Pv Central venous pressure
MAP = Pa Mean arterial pressure
MCP Mean circulatory pressure
Va Volume of blood in arterial compartment
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Va0 Volume of blood in arterial compartment at MCP
Vv0 Volume of blood in venous compartment at MCP
CPLa Arterial compliance
CPLv Venous compliance
CPLratio Ratio of venous over arterial compliance
SVR Systemic vascular resistance
CO Cardiac output
COL Cardiac output (left side)
COR Cardiac output (right side)
HR Heart rate
SV Stroke volume
kc unit conversion factor – contractility
CNT Contractility
additional for Frank-Starling-Baroreceptor model
MAPset Mean arterial pressure set point
HRgain Gain for heart rate control
additional for Constrained-Frank-Starling-Barorecep-
tor model
PaS Pressure in arterial compartment when stressed
PvS Pressure in venous compartment when stressed
VaS Volume in arterial compartment when stressed
VvS Volume in venous compartment when stressed
slopeMAP slope for arterial pressure-volume relationship
intMAP intercept for arterial pressure-volume relationship
slopeCVP slope for venous pressure-volume relationship
intCVP intercept for venous pressure-volume relationship
S1 Sympathetic tone coefficient – Chronotropy
S2 Sympathetic tone coefficient – Contractility
SVmax maximum for stroke volume-CVP relationship
SV50 half-volume for stroke volume-CVP relationship
nSV "Hill factor" for stroke volume-CVP relationship
Pharmacokinetic term Description Description
Recirculatory model
R0 doserate of zero order infusion
tau duration of zero order infusion
Cart Arterial magnesium concentration (total)
Cven Venous magnesium concentration (total)
Cart,e Arterial magnesium concentration (endogenous)
Cven,e Venous magnesium concentration (endogenous)
Cart,x Arterial magnesium concentration (exogenous)
Cven,x Venous magnesium concentration (exogenous)
Vlung Apparent distribution volume of the lung
CL Clearance
Vbody  Apparent distribution volume of the body
compartment
PS Permeability-surface area product of deep
compartment
Vdeep  Apparent distribution volume of the deep
compartment
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